10-Q: Shineco, Inc. Reports Third Quarter Fiscal Year 2025 Results

Shineco, Inc. reports a net loss of $21.46 million for the nine months ended March 31, 2025, driven by losses from discontinued operations.

Summary

• Shineco, Inc., a Delaware-incorporated holding company, released its unaudited condensed consolidated financial statements for the third quarter of fiscal year 2025.
• For the nine months ended March 31, 2025, the company reported a net loss of $21.46 million, compared to a net loss of $4.08 million for the same period in 2024.
• The net loss from continuing operations was $5.58 million, while the net loss from discontinued operations was $15.87 million.
• Revenue for the nine months ended March 31, 2025, was $259,040, a decrease from $459,572 in the prior year.
• The company's management has expressed substantial doubt about its ability to continue as a going concern for the next twelve months.
• As of March 31, 2025, the company had negative working capital of $13.7 million and an accumulated deficit of $73.1 million.
• The company has taken measures to enhance liquidity, including securities purchase agreements and an underwritten public offering.
• The company is involved in legal proceedings, including a civil complaint against Life Science and a lawsuit against Biowin.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant net losses, decreased revenue, and concerns about the company's ability to continue as a going concern. While the company has taken steps to improve liquidity, the overall financial performance is weak.

Positives

• The company has taken measures to enhance liquidity, including securities purchase agreements and an underwritten public offering.
• General and administrative expenses decreased by $2.4 million, or 32.17%, for the nine months ended March 31, 2025.
• The company successfully renewed its HNTE certification with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2025.

Negatives

• The company reported a net loss of $21.46 million for the nine months ended March 31, 2025.
• Revenue decreased to $259,040 for the nine months ended March 31, 2025.
• The company's management has expressed substantial doubt about its ability to continue as a going concern.
• As of March 31, 2025, the company had negative working capital of $13.7 million.
• The company is involved in legal proceedings, including a civil complaint against Life Science and a lawsuit against Biowin.
• The company's disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this Quarterly Report due to material weaknesses.

Risks

• The company's management has expressed substantial doubt about its ability to continue as a going concern.
• The company is involved in legal proceedings, including a civil complaint against Life Science and a lawsuit against Biowin.
• The company's disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this Quarterly Report due to material weaknesses.
• The company's operations are conducted primarily in the PRC and subject to special considerations and significant risks not typically associated with companies operating in North America and/or Western Europe.
• If the Company fails to satisfy the Nasdaq Stock Market LLCs (Nasdaq) continued listing requirements, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist its common stock.

Future Outlook

The company's management believes that the company's current access to loans, equity financing as well as financial support from its stockholders will be sufficient to meet its working capital needs for at least the next 12 months. The Company intends to continue to carefully execute its growth plans and manage market risk.

Industry Context

The company operates in the health and well-being sector, with a focus on plant-based products and rapid diagnostic products. The company's performance is affected by factors such as market demand, competition, and regulatory changes in the PRC.

Legal Proceedings

• On October 31, 2024, the Plaintiff submitted a civil complaint to the Beijing Chaoyang District Peoples Court against Life Science and the Party A (the Civil Complaint).
• On November 8, 2024, Zhejiang Shijin Packaging Co., Ltd. (the Plaintiff) submitted a civil complaint to the Peoples Court of Deqing County, Zhejiang Province (the Court) against the Companys subsidiary Biowin.
• On April 16, 2025, Bank of Jiangsu (the Plaintiff) commenced a lawsuit against the Companys subsidiary, Biowin, in the Jiangsu Changzhou High-Tech Industrial Development Zone Peoples Court.

Related Party Transactions

• The Company has made temporary advances to certain stockholders and senior management of the Company and to other entities that are either owned by family members of those stockholders or to other entities that the Company has investments in.
• The Companys related parties provide a guarantee for the Companys bank loans.
• As of March 31, 2025 and June 30, 2024, Chongqing Wintus (New Star) Enterprises Group (Chongqing Wintus) provided a guarantee that amounted to US$ 688,906 and US$ 687,999 for a bank loan borrowed by Chongqing Yufan, a related party of the Company until December 28, 2025.
• The Company entered into a two-year lease agreement for the lease of office space from a related party company, of which the CEO is the Companys shareholder.

Stakeholder Impact

• Shareholders: The net loss and concerns about the company's ability to continue as a going concern may negatively impact shareholder value.
• Employees: The company's financial difficulties may lead to cost-cutting measures, including potential layoffs or reduced compensation.
• Customers: The company's ability to provide products and services may be affected by its financial situation.
• Creditors: The company's ability to repay its debts may be at risk due to its financial difficulties.

Next Steps

• The company intends to continue to carefully execute its growth plans and manage market risk.
• The company is committed to monitoring the effectiveness of measures to address material weaknesses in internal control and making any changes that are necessary and appropriate.

Key Dates

Keywords

Shineco, financial results, net loss, revenue, going concern, reverse stock split, legal proceedings, liquidity, Biowin, Fuzhou Meida, discontinued operations, convertible notes, securities purchase agreement, internal control, material weaknesses